PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
- Conditions
- HypercholesterolemiaDyslipidemia
- Interventions
- Biological: 1 mg/kg every 2 weeksBiological: 2 mg/kg every 4 weeksBiological: 4 mg/kg every 4 weeksBiological: 8 mg/kg every 8 weeksBiological: 12 mg/kg every 8 weeksBiological: PlaceboBiological: 4 mg/kg every 8 weeks
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01163838
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
- Conditions
- Healthy
- Interventions
- Drug: ATR-107 (PF-05230900) IV InfusionDrug: Placebo SC InjectionDrug: ATR-107 (PF-05230900) SC InjectionDrug: Placebo IV Infusion
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT01162889
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2867
- Registration Number
- NCT01163253
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin, Boston, Massachusetts, United States
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2011-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01161069
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT01161472
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01159626
- Locations
- 🇺🇸
Pfizer Investigational Site, Glendale, California, United States
Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT01159496
- Locations
- 🇫🇷
Pfizer Investigational Site, Rueil-Malmaison, France
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
- Conditions
- Early Breast Cancer
- Interventions
- Other: Aromasin (exemestane)
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 89
- Registration Number
- NCT01155063
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
- Conditions
- Non Squamous Lung Cancer
- Interventions
- Drug: treatment
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 343
- Registration Number
- NCT01154140
- Locations
- 🇮🇳
Tata Memorial Centre, Tata Memorial Hospital,, Mumbai, Maharashtra, India
🇮🇹Struttura Operativa Complessa Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
🇯🇵The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
BeneFIX Drug Use Results Survey [All-Case Surveillance]
- Conditions
- Hemophilia B
- Interventions
- Drug: Nonacog Alfa (Genetical Recombination)
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 314
- Registration Number
- NCT01154231
- Locations
- 🇯🇵
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan